Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Past Presentation MaterialsConference on FY2026.12 Q2 Financial Results
FY2026 Q2 Overview
Dr. Osamu Okuda,
President & CEO
FY2026 Q2 Overview of Development Pipeline
Tsukasa Kusano,
Executive Vice President, Head of Project & Lifecycle Management Unit
FY2026 Q2 Consolidated Financial Overview (Core)
Iwaaki Taniguchi,
Director, Executive Vice President & CFO
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2025(Integrated Report)
Past Annual Report
What's New
-
Transcript (including Q&A) for Conference on FY2026.12 Q2 Financial Results
-
Conference on FY 2026.12 Q2 Financial Results
-
Financial Results for Second Quarter of Fiscal Year 2026 (Jan-Jun 2026)
-
Transcript (including Q&A) for Chugai Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
-
Chugai Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
-
Vamikibart Filed for Regulatory Approval in Japan for Uveitic Macular Edema Associated with Non-Infectious Uveitis
-
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
-
Chugai Files for Additional Indication of Tecentriq for Adjuvant Treatment of MSI-High Colon Cancer
-
Chugai and UCSF Establish Master Collaboration Agreement for Drug Discovery Research - A Framework to Streamline Future Research Projects-
-
Announcement of Partnership with the Japan Basketball Association (JBA)
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
